藤梨根提取物抗肺癌作用的实验研究
|
摘要
研究背景和目的 原发性支气管肺癌(简称肺癌)是呼吸系统最常见的恶性肿瘤，是近年来发病率较高的恶性肿瘤。手术切除是治疗肺癌的首选方法，但由于肺癌患者早期缺乏特异性临床症状和体征，故其早期诊断率较低，确诊时多数患者已处于中晚期，常失去手术机会，只能辅以放疗和化疗等处理。多数肺癌患者在确诊后1年内死亡，其5年生存率低于15％。化疗仍是肺癌综合治疗的重要手段。目前临床常用的几种联合化疗方案，虽然有效率有所提高，但仍不理想，故国内外学者均在致力于寻找对肺癌更为有效的药物。随着研究的深入，从中草药中提取和寻找防治肿瘤的有效成分已成为治疗肿瘤的希望和新途径。
藤梨根为猕猴桃科猕猴桃属软枣猕猴桃的根，具有清热解毒、消肿疥、祛风湿的功效。临床上常用于抗肿瘤治疗，尤其对消化道肿瘤疗效较佳。近年研究发现，藤梨根复方制剂体外对多种肿瘤有抑制作用，可通过多种途径发挥抗肿瘤作用，其药理研究和临床验证受到广泛关注。有关藤梨根对肺癌的作用尚未见报道，本研究以人肺腺癌细胞株A549细胞作为研究对象，从体内外两条途径观察藤梨根提取物对人肺癌细胞的生长抑制作用和凋亡诱导作用，并对其可能机制进行探讨，以期为进一步临床应用提供实验依据。
方法 本研究分三部分
1．藤梨根提取物对人肺癌细胞体外抑制作用及机制的实验研究。体外培养人肺癌细胞株A549细胞；采用倒置显微镜观察藤梨根提取物作用前后细胞形态学变化；台盼蓝计数活细胞绘制不同浓度药物作用后细胞的生长曲线；四甲基偶氮唑蓝(MTT)比色法测定不同浓度药物作用不同时间对A549细胞生长的抑制率；集落形成试验观察不同浓度药物对细胞集落形成的影响；流式细胞术、~3H-TdR掺入
Background and Objective:
Now in our country, the morbidity and mortality of lung cancer locate the first place in all malignant tumor. Surgical operation excision is the first treatment to cures lung cancer.But due to the lack of specificity sings and symptoms in clinic, the rate of early diagnosis is low.When they obtain final diagnosis, most of them were in a advanced stage and lost the opportunity of surgery .Only radiotherapy, chemotherapy and other conservation treatment can be given to them.So most patients of lung cancer were died in one year.The survival rate of 5 years was lower than 15%. Chemotherapy is main method to treat lung cancer besides surgery.Although effective power has increase to some extent, now the combined chemotherapy scheme that frequently used in clinical was still no do well enough.For the past few years, to extract and look for active component of anti-tumor from Chinese Herbal Medicine become new method and wish to treating cancer.
Radix Actinidiae is the root of Actinidia arguta Planch in Actinidiaceae.It have the function of heat-clearing and detoxicating, detumescence , eliminating rheumatic.Frequently to be used to treat tumor in clinic. Especially have good effect to alimentary tract cancer. Recently study surgest that Radix Actinidiae extractive have inhibitory action to many kinds of cancer in vitro.People pay close attention to pharmacoresearch and clinic probation.There is not research were done on if it have function of anti- lung cancer.We apply it to lung adenocarcinoma cell line A549
藤梨根为猕猴桃科猕猴桃属软枣猕猴桃的根，具有清热解毒、消肿疥、祛风湿的功效。临床上常用于抗肿瘤治疗，尤其对消化道肿瘤疗效较佳。近年研究发现，藤梨根复方制剂体外对多种肿瘤有抑制作用，可通过多种途径发挥抗肿瘤作用，其药理研究和临床验证受到广泛关注。有关藤梨根对肺癌的作用尚未见报道，本研究以人肺腺癌细胞株A549细胞作为研究对象，从体内外两条途径观察藤梨根提取物对人肺癌细胞的生长抑制作用和凋亡诱导作用，并对其可能机制进行探讨，以期为进一步临床应用提供实验依据。
方法 本研究分三部分
1．藤梨根提取物对人肺癌细胞体外抑制作用及机制的实验研究。体外培养人肺癌细胞株A549细胞；采用倒置显微镜观察藤梨根提取物作用前后细胞形态学变化；台盼蓝计数活细胞绘制不同浓度药物作用后细胞的生长曲线；四甲基偶氮唑蓝(MTT)比色法测定不同浓度药物作用不同时间对A549细胞生长的抑制率；集落形成试验观察不同浓度药物对细胞集落形成的影响；流式细胞术、~3H-TdR掺入
Background and Objective:
Now in our country, the morbidity and mortality of lung cancer locate the first place in all malignant tumor. Surgical operation excision is the first treatment to cures lung cancer.But due to the lack of specificity sings and symptoms in clinic, the rate of early diagnosis is low.When they obtain final diagnosis, most of them were in a advanced stage and lost the opportunity of surgery .Only radiotherapy, chemotherapy and other conservation treatment can be given to them.So most patients of lung cancer were died in one year.The survival rate of 5 years was lower than 15%. Chemotherapy is main method to treat lung cancer besides surgery.Although effective power has increase to some extent, now the combined chemotherapy scheme that frequently used in clinical was still no do well enough.For the past few years, to extract and look for active component of anti-tumor from Chinese Herbal Medicine become new method and wish to treating cancer.
Radix Actinidiae is the root of Actinidia arguta Planch in Actinidiaceae.It have the function of heat-clearing and detoxicating, detumescence , eliminating rheumatic.Frequently to be used to treat tumor in clinic. Especially have good effect to alimentary tract cancer. Recently study surgest that Radix Actinidiae extractive have inhibitory action to many kinds of cancer in vitro.People pay close attention to pharmacoresearch and clinic probation.There is not research were done on if it have function of anti- lung cancer.We apply it to lung adenocarcinoma cell line A549
引文
1．王志瑾．肺癌流行病学．肿瘤防治杂志，2002，9(1)：1-5．
2. Bast RC, Kule DW, Pollock RE, et al. Holland-Frei Cancer Medicine[M]. 5th Ed. Bc Decker, chap, 2000: 120.
3．李连弟，饶克勤，中国11市县肿瘤发病和死亡登记资料统计分析(1988年．1992年)．中国肿瘤，2000，9(10)：435-477．
4．林小萍，王庆生，刘新民．肺癌发病趋势及分析．天津医科大学学报，2000，6(2)：129-132．
5．蒋耀光，周清华，主编．现代肺癌外科学．北京：人民军医出版社，2003．460．
6．潘云华，潘琦，王泽时，等．复方三根制剂抗T739小鼠肺癌转移的实验研究．浙江中西医结合杂志，2005，15(2)：76-78．
7．冯正权，郭勇，朱宁希，等．复方三根制剂逆转多药耐药的实验研究．中国肿瘤，2003，12(6)：370-371．
8．林玲，章巧萍，俞丽霞，等．三根祛瘤方对DNA损伤的保护和对化疗药减毒增效作用的研究．浙江中医学院学报，1997，21(5)：30-32．
9．钟振国，张凤芬，甄汉深，等．美味猕猴桃根提取物抗肿瘤作用的实验研究．中医药学刊，2004，22(9)：1705-1707．
10．钟振国，张雯艳，张凤芬，等．中越猕猴桃根提取物的体外抗肿瘤活性研究。中药材，2005，28(3)：215-218．
11．张凤芬，钟振国，张雯艳，等．山梨猕猴桃根提取物的体外抗肿瘤活性研究．中医药学刊，2005，23(2)：261-263．
12．李昊，杨慧萍，杨凡等．藤梨根对胃癌细胞作用的实验研究河北中医，2004，26(4)：314-315．
13．金永日，桂明玉，马冰如，等．软枣猕猴桃根化学成分的研究．中国药学杂志．1998，33(7)：402-404．
14．季于彬．抗癌中药药理与应用．黑龙江：黑龙江科技出版社，1999．489．
15．陈德轩，潘立群．抗肿瘤植物药藤梨根．中药材，2004，27(2)：86-87．
16．翟延君，冯夏红，康廷国，等．软枣猕猴桃不同药用部位微量元素的含量测定．微量元素与健康研究，1996，13(3)：32-33．
17．朱秀山，许继平，黄德辉，等．壁虎藤梨根治疗胃癌临床及实验研究．中国民间疗 法，1999，(3)：43-44．
18．杭州肿瘤医院．草药藤梨根治疗癌症的情况调查．中草药通讯，1970，1(1)：18．
19．李蕾，金长娟．夏星方在食管癌粘液痰中的应用．现代中西医结合杂志，2000，9(15)：1445．
20．张新，孙华．余桂清治疗食管癌经验．中国中西医结合脾胃杂志，1999，7(3)：167．
21．闫洪飞，卢雯平．孙桂芝教授治疗消化道肿瘤的经验．中国中西医结合外科杂志，2002，8(1)：46．
22．杨继泉，张斌斌．中药治疗中晚期胃癌102例疗效分析．浙江中西医结合杂志，2000，10(6)：334-335．
23．郭勇，吴仙俐．大肠癌的中西医治疗规律初探．浙江中医学院学报，1992，16(4)：28．
24．周兴兆．唐福安论肺癌证治．浙江中医学院学报，2000，24(2)：45-46．
25．唐文秀．中医药治疗晚期原发性非小细胞肺癌临床观察．中医杂志，1994，35(5)：283．
26．夏黎明，林起铨，呈飞雪，等．中医药治疗原发性肺癌临床疗效探析．中国中医基础医学杂志，2001，7(8)：612-613．
27．周兰．中西医结合治疗中晚期恶性肿瘤50例．辽宁中医学院学报，2002，4(1)：45-46．
28．霍介格，杨炳奎．胶质瘤中医及中西医结合治疗进展．江苏中医药，2002，23(8)：44-46．
29．于志峰，戴锡孟．中医药治疗急性白血病的研究概况．天津中医，2000，17(4)：51-53．
30．阙克清．软枣猕猴桃抗癌作用的实验研究．湖南医学，1985，(5)：21．
31．林玲，章巧萍，俞丽霞，等．三根祛瘤方对小鼠S180的抗瘤和免疫作用的研究．中草药，1995，17(10)：33-35．
32．林玲，章巧萍，俞丽霞，等．三根祛瘤方对Lewis肺癌等的抗肿瘤作用实验研究．浙江中医学院学报，1995，19(1)：37-39．
33．张爱琴，王泽时．三根祛瘤方对大鼠胃癌癌前病变阻断机理实验研究．中国中西医结合杂志，1998，18(1)：35-36．
34．陈华．三根祛瘤方抗瘤作用研究．现代中西医结合杂志，2001，10(23)：2237-2239．
35．谢长生，周维顺，冯正权，等．复方三根制剂对MDR细胞株K562／ADR和K562／VCR逆转作用的研究．中国实验方剂学杂志，2003，9(4)：26-30．
36．郭勇，谢长生，冯正权．复方藤梨根制剂体外对MDR细胞株K562／ADR和K562／VCR细胞积聚和外排阿霉素(ADR)的影响研究．中国现代应用药学杂志，2002，19(4)：268-272．
37．张海波，姚庆华，郭勇，等．复方藤梨根制剂对PG细胞生长调控的研究．浙江中西医结合杂志，2004，14(10)：616-617．
38．姚庆华，郭勇，杨维泓，等，复方藤梨根制剂上调PG细胞细胞间隙连接通讯功能的研究，肿瘤研究与临床，2004，16(5)：302-304
39．尹丽慧，叶人，吴建波，等．蔡氏扶正消症汤对胃癌细胞增殖的抑制作用研究．中医药学刊，2005，23(3)：473-475．
40．张光霁．藤蟾方抑瘤及其诱导肿瘤细胞凋亡的实验研究。浙江临床医学，2004，6(5)：356-357．
41．张光霁，申力．藤蟾方对荷瘤小鼠免疫功能影响的实验研究辽宁中医杂志，2004，31(6)：523．
42．张光霁．藤蟾方对S_(180)小鼠p53和PCNA蛋白表达的影响．现代中西医结合杂志，2004，13(12)：1566-1567．
43．王文萍，姜良铎，饭乡正明，等．肠积消对IFN_γ的诱导及肺转移的抑制．中国中医基础医学杂志，2001，7(12)：903-904．
44．王文萍，姜良铎，王垂杰，等．中药复方肠安泰胶囊对大肠癌肺转移模型小鼠肠粘膜T细胞及NK细胞的诱导．北京中医药大学学报，2001，24(4)：34-36．
45. Mosmain T, Murphy PC, Henderson FW. Rapid colorunetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Imm Method, 1983, 65(2): 55-59.
46. Carmichael J, Degraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res, 1987, 47: 936-942.
47．张卓然，主编。培养细胞学与细胞培养技术．上海：上海科学技术出版社，2004。310．
48. Salmon SE. Humen tumor colony assay and chemosensitivity testing. Cancer Treat Rep, 1984, 68(1): 117-125.
49．韩锐，主编．抗癌药物研究与实验技术．北京：北京医科大学中国协和医科大学联合出版社，1997．4．
50. JI Whang, HI Moon, OP Zee. Phytochemical Constituents of Actinidia arguta. Korean Journal of Pharmacognosy, 2000, 31(3): 357-363.
51．高慧，傅松滨，董辉．肿瘤中p16基因的研究进展国外医学遗传学分册，1999，22(2)：61-65．
52. Schafer KA .The cell cycle:a review.Vet Pathol, 1998,35(6):461-478.
53. Barlogie B,Raber MN,Schumann J,et al. Flow cytometry inclinical cancer research. Cacer Res, 1983, 43(9):3982.
54. Visakorpi T,Holli K,Hakama M.High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma.Acta Oncol, 1995,34(5):605.
55. Stein H,Gerdes J,Kirchner H,et al.Immunohistological analysis of Hodgkin'sand Sternberg-reed cells:detection of a new antigen and evidence for selective IgG uptake in the absence of B cell,T cell and histiocytic markers.J Cancer Res Clin Oncol,1981,101(1):125-134.
56. Gerdes J, Schwab U,Lemke H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.Int J Cancer, 1983,31(1): 13-20.
57. Schluter C,Duchrow M,Wohlenberg C,et al.The cell proliferation-associated nuclear antigen of antibody Ki-67:A very large,ubiquitous nuclear protein with numerous repeated element,representing a new kind of cell cycle maintaining protein. J Cell Biol, 1993,123:513-522.
58. Schluter C,Duchrow M,Wohlenberg C,et al.Molecular cloning of the cell proliferation-associated nuclear antigen defined dy antibody Ki-67:a unique gene encoding for a new PEST protein.J Cell Biol, 1993, 123(4): 635-642.
59. Bruno S,Darzynkiewicz Z.Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells.Cell Prolif, 1992,25(1): 31-40.
60. Gerds J,Li L,Schluter C,et al.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined dy monoclonal antibody Ki-67.Am J Pathol, 1991, 138(4):867-873.
61.Verheijen R,Kuijpers HJ,Schlingemann RO,et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen.I.Intracellular localization during interphase. J Cell Sci,1989,92(pt1): 123-130.
62. Verheijen R,Kuijpers HJ,Van Driel R,et al.Ki-67 detects a nuclear matrix- associated proliferation-related antigen.II.Localization in mitotic cells and association with chromosomes. J Cell Sci, 1989, 92: 531-540.
63. Sawhney N, Hall PA. Ki-67 structure, function, and new antibodies. J Pathol, 1992. 168(2): 161-162.
64. Sasaki K, Murakami T, Kawasaki M, et al. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Pathol, 1987, 133(3): 579-584.
65. Duchrow M, Schulter C, Wohlenberg C, et al. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined dy monoclonal antibody Ki-67. Cell Prolif, 1996, 29(1): 1-12.
66. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhance ment method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histoche Cytoche, 1991, 39(6): 741-748.
67. Key G, Meggetto F, Becker MH, et al. Immunobiochemical characterization of the antigen detected by monoclonal antibody IND. 64. Evidence that IND. 64 reacts with the cell proliferation associated nuclear antigen previously defined by Ki-67. Virchows Arch B Cell Pathol Incl Mol Pathol, 1992, 62(4): 259-262.
68. Key G, Petersen JL, Becher MH, et al. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J Clin Pathol, 1993, 46(12): 1080-1084.
69. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 1984, 133(4): 1710-1715.
70. Linden MD, Torres FX, Kubus J, et al. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol, 1992, 97(SSuppl 1): S4-13.
71. Pich A, Ponti R, Valente G, et al. MIB, Ki-67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol, 1994, 47(1): 18-22.
72．许玲，刘嘉湘．益肺抗瘤饮抑制肺癌细胞增殖的实验研究．中国中西医结合杂志，1996．16(8)：486-488．
73．程小丽，陈葳，周冬枝，等．益气养血保元对肺癌细胞Ki-67的影响。现代中医，1999，12(4)：39-40．
1. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer, 1994, 73(8): 2013-2026
2．李学军，杨叔禹．中医药促进细胞凋亡机理研究进展．中国中医基础医学杂志，2003，9(1)：73-74．
3．李晓波，季莉莉，王钊．中药对细胞凋亡影响的研究进展．中药材，2002，25(2)：135-139．
4．钟振国，张凤芬，甄汉深，等．美味猕猴桃根提取物抗肿瘤作用的实验研究．中医药学刊，2004，22(9)：1705-1707．
5．李昊，杨慧萍，杨凡等．藤梨根对胃癌细胞作用的实验研究．河北中医，2004，26(4)：314-315．
6．张光霁．藤蟾方抑瘤及其诱导肿瘤细胞凋亡的实验研究．浙江临床医学，2004，6(5)：356-357．
7．沈洁云，燕忠生．中药抗肿瘤作用机理研究进展．中医杂志，2000，41(7)：437．
8．涂硕，韦星．中药诱导肺癌细胞凋亡的研究进展．江西医学院学报，2005，4(3)：164-166．
9. Bour ES, Ward LK, Cornman GA, et al. Tumor necrosis factor-alpha-induced apoptosis in hepatocytes in long-term culture.Am J Pathol, 1996, 148: 485-495.
10. Hengarter, M. Death by crowd control. Science, 1998, 281 (5381): 1298-1299.
11. Cummings MC, Winterford CM, Walker NI. Apoptosis. Am J Surg Pathol, 1997, 21: 88-101.
12. Granville DJ, Carthy CM, Hunt DWC, et al. Apoptosis: molecule aspects of cell death and disease. Lab Invest, 1998, 78: 893-913.
13. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer, 1972, 26: 239-257.
14. Kuan NK, Passaro E. Apoptosis: Programmed cell death. Arch Surg, 1998, 133: 773-775.
15. Hacker G. The morphology of apoptosis. Cell Tissue Res, 2000, 301 (1): 5-17.
16. Nagata S, Golstein P. The Fas death factor. Science, 1995, 267: 1449-1456.
17. Wyllie A. An endonuclease at last. Nature, 1998, 391: 20-21.
18. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytest riggers specific recognition and removal by macrophages. J Immunol, 1992, 148: 2207-2216.
19. Wyllie AH. Apoptosis: an overview. Br Med Bull, 1997, 53: 451-465.
20. Peter ME,Heufelder AE,Hengartner MD.Advances in apoptosis research .Proc Natl Acad Sci,1997,94:12736-12737.
21. Hetts SW.To die or not to die:an overview of apoptosis and its role in disease. JAMA, 1998,279(4):300-307.
22. Green,DR .Apoptotic pathways: paper wraps stone blunts scissors. Cell,2000,102 (1) .1-4.
23. Lyons SK,Clarke AR.Apoptosis and carcinogenesis.Br Med Bull,1997,53 (3): 554-569.
24. Huang P,Oliff,A. Signaling pathways in apoptosis as potential targets for cancer therapy.Trends Cell Biol,2001,11 (8):343-348.
25. Makin G,Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?.Breast Cancer Res,2001,3(3):150-153.
26. Haq R,Zanke B.In hibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance.Cancer Metastasis Rev, 1998,17(2): 233-239.
27. Inoue S,Salah-Eldin AE,Omoteyama K. Apoptosis and anticancer drug resistance. Hum Cell, 2001, 14(3):211-221.
28. Ravi D, Panikkar KR,Nair MK,et al.Apoptosis:future directions in cancer therapy .Natl Med J India, 2000,13(2):71-78.
29. Kolenko VM,Uzzo RG,Bukowski R,et al.Caspase-dependent and -independent death pathways in cancer therapy.Apoptosis,2000,5(1): 17-20.
30. Kaufmann SH,Earnshaw WC.Induction of apoptosis by cancer chemotherapy.Exp Cell Res,2000,256(1):42-49.
31. Makin G.Targeting apoptosis in cancer chemotherapy.Expert Opin Ther Targets, 2002, 6(1):73-84.
32. Johnstone RW,Ruefli AA,Lowe SW.Apoptosis:a link between cancer genetics and chemotherapy.Cell,2002,108(2):153-164.
33. Gong JP,Traganos F,Darzynkiewicz Z.A selective procedure for DNA extraction from apoptotic cells appliabie for gel electrophoresis and flow cytometry.Analy Biochem,1994,218:314-319.
34. Liming P,Bradely CJ,Liu JJ. The correlativity analysis of six methods of detecting apoptosis.Chin Med Sci J,1999,14(3):145-151.
35.Nicoletti I,Migliorati G,Pagliaui MC,et al. Arapid and simple method for measuring thymocyte apoptosiss by propidium iodide staining and flow cytometry.J Immunol Methods, 1991, 139(2):271-279.
36. Huschtscha LI,Jeitner TM, Anderson CE, et al. Identification of apoptotic and necrotc human leukemiac cells by flow cytometry.Experimental Cell Res, 1994,212:161-165.
37. Mirakian R,Nye K,Palazzo FF,et al.Methods for detecting apoptosis in thyroid disease.J Immunol Methods,2002,265 (1-2): 161-175.
38. Stassi G,Todaro M,Bucchieri F,et al. Fas/Fas ligand-driven T cell apoptosis as a consequence of infective thyroid immunop rivilege.J mmunol, 1999,162: 263-267.
39. Bretz JD,Baker JR.Apoptosis and autoimmune thyroid disease: following a TRAIL to thyroid destruction?. Clin Endocrinol,2001,55:1-11.
40. Kischkel FC,Lawrence DA,Chuntharapai A,et al.Apo2L/TRA IL-dependent recruitment of endogenous FADD and Caspase-8 to death receptors 4 and 5.Immunity, 2000,12 (6): 611-620.
41. Rodriguez M,Schaper J. Apoptosis : measurement and technical issues. J Mol Cell Cardio,2005,38(1): 15-20.
42. Kobayashi T,Ruan S,Jabbur JR,et al.Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ,1998,5(7):584-591.
43. Borner C.The Bcl-2 protein family:sensors and checkpoints for life- or-death decisions.Mol Immunol,2003,39:615-647.
44. Vander Heiden MG,Chandel NS,Williamson EK,et al.Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria.Cell, 1997,91(5): 627-637.
45. Kroemer G, Zamzami N, Susin SA. Mitochondrial, control of apoptosis. Immunol Today, 1997,18(1):44-51.
46. Scorrano L,korsmeyer SJ.Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun,2003,304:437-444.
47. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins.J Cell Med, 2003,7:249-257.
48. Sprick MR,Walczak H.The interplay between the bcl-2 family and death receptor-mediated apoptosis.Biochim Biophys Acta, 2004,1644:125-132.
49. Cory S,Adams JM.The Bcl-2 family regulators of the cellular life-or-death switch. Nat Rev Cancer, 2002,2:647-656.
50. Farrow SN,White JH,Martinou I,et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature,1995,374(6524):731-733.
51. Fernandez MC,Bick RJ.Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+.Oncogene, 1996,12(11): 2259-2266.
52. Haddad JJ.On the antioxidant mechanisms of Bcl-2: a retrospective of NF-kappaB signaling and oxidative stress. Biochem Biophys Res commim, 2004,322:355-363.
53. Chen GG,Liang NC,Lee JF,et al.Over-expression of Bcl-2 against Pteris semipinnata L-induced apoptosis of human colon cancer cells via a NF-kappa B-related pathway. Apoptosis, 2004,9:619-627.
54. Jiang M,Milner J.Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells.Genes Dev,2003,17(7):832-837.
55. Godefroy N,Bouleau S,Gruel G,et al. Transcriptional repression by p53 promotes a Bcl-2-insensitive and mitochondria-independent pathway of apoptosis. Nucleic Acids Res,2004,32:4480-4490.
56. Oltvai ZN,Milliman CL,Korsmeyer SL.Bcl-2 heterodimerizes in vivo with a conserved homdog ,Bax,that accelerates programmed cell death.cell, 1993, 74(4): 609-619.
57. Apte SS,Mattei MG,Olsen BR.Mapping of the human Bax gene to chromosome 19q13.3-19q13.4 and isolation of a novel alternatively spliced transcript,Bax delat.Genomics,1995,26:592-594.
58. Coultas L,Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol, 2003,13:115-123.
59. Krajewski S,Krajewska M,Shabaik A,et al.Immunohistochemical determination of in vivo diatribution of Bax,a dominant inbitor of Bcl-2.Am J Pathol, 1994,145: 1323-1336.
60. Wolter KG, Hsu YT, Smith CL, et al. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol,1997,139(5): 1281-1292.
61. Antonsson B,Conti F,Ciavatta A,et al. Inhibition, of Bax channel-forming activity by Bcl-2. Science,1997 ,277(5324) :370-372.
62. Li Y,Bhuiyan M,Mohammad RM,et al. Induction of apoptosis in breast cancer cells by TPA.Oncogene, 1998,17:2915-2920.
63. Zami N,Brenner C,Marzo I Susin SA,et al. Subcelluar and submitochondrial mode of action of Bcl-2-like oncoproteins.Oncogene, 1998,16:2265-2282.
64. Korsmeyer SJ .BCL-2 gene family and the regulation of programmed cell death. Cancer Research, 1999, 59(Suppl):1693-1700.
65. Adams JM,Cory S.The Bcl-2 protein family: Arbittrs of Cell Survival.Science, 1998,281:1322-1326.
66. Deveraux GL,Reed JC. IAP family proteinssuppressor of apoptosis. Genes Dev, 1999, 13:239-252.
67. Lacasse EC,Baird S,Kormeluk R,et al. The inhibitors of apoptosis (IAPs)and their emerging role in cancer.Oncogene, 1998,17:3247-3259.
68. Ambrosini G,Adida C,Altier Dc,et al. A novel anti-apoptosis gene, surviving expressed in cancer and lymphoma .Nat Med, 1997, 3(8):917-912.
69. Ambrosini G,Adida C,Sirugo G,et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998,273 (18) : 11177-11182.
70. Chantalat L,Skoufias DA,kleman JP,et al. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual α-helicals extensions.Mol Cell,2000,6 (1): 183-189.
71.Akoufias DA,Mollinari C,Lacrax FB,et al.Human survivin is a kinetochore- associated passenger protein. J Cell Biol,2000,151(7): 1575-1582.
72. Gianani R,Jarboe E,Orlicky D,et al. Expression of Survivin in normal, hyperplastic and neoplastic colonic mucosa.Hum Pathol,2001,32(1):119 - 125.
73. Shinozawa I,Inokuchi K,Wakahayashi I,et al.Disturbed expression of the anti -apoptosis gene,Survivin and EPR-1 in hematological malignancies.Leuk Res, 2000,24(11): 965-970.
74. Shin S,Sung BJ,Cho Ys,et al.An anti-apoptotic protein human survivin is a direct inhibitor of Caspase-3 and Caspase-7.Biochemistry.2001, 40(4):1117-1123.
75. Adida C,Crotty PL,McGrath J,et al.Developmentaly regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse diferentiation. Am J Pathol, 1998,152(1):43-49.
76. Andrade F,Roy S,Nicholson D,et al.Granzyme B directly and efficiently cleaves several downstream Caspase substrates:implications for CTL-induced apoptosis.Immunity, 1998, 8(4):451-460.
77. Ito T,Shirak K,Sugimoto K,et al. Survivin promotes cell proliferation in human hepatocelluarcarcinoma.Hepatology,2000,31(5):1080-1085.
78. Suzuki A,Ito T,Kawano H,et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas - mediated cell death. Oncogene,2000,19(10): 1346-1353.
79. Altieri Dc. Coupling apoptosis resistance to the cellular stress response : The IAP-Hsp90 connection in cancer. Cell Cycle,2004,3 (3) 255-256.
80. Du C,Fang M,Li Y,et al.Smac,a mitochondrial protein that promotes cytochrome c-dependent Caspase activation by eliminating LAP inhibition. Cell, 2000,102:33-42.
81. Verhagen AM,Ekert PG,Pakusch M,et al.Identification of DIABLO,a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 2000,102(1):43-53.
82. Li F,Ambrosini G,Chu EY,et al.Control of apoptosis and mitotic spindle checkpoint by surviving.Nature, 1998,396(6711):580-584.
83. Lin FR,Wang Y,Wang RQ,et al. Expression of survivin,Fas,bcl-2 and bax in bone marrow cells from acute myeloid leukemia patients and its clinical significance. Zhongguo-Shi-Yan-Xue-Ye-Xue-Za-Zhi,2003,11(3): 259-262.
84. Nguyen VN,Mirejovsky P,Mirejovsky T,et al.Expression of cyclin Dl,Ki-67 and PCNA in non - small cell lung cancer: prognostic significance and comparion with P53 and Bcl-2. Acta Histochem,2000,102(3): 328-338.
85. Tamm I,Wang Y,Sausville E,et al.IAP-family protein survivin inhibits Caspase activity and apoptosis induced by Fas(CD95),Bax,Caspase,and anti cancer drags. Cancer Res, 1998,58(23):5315-5320.
86. Ray SK,Fidan M,Nowak M.Oxidative stress and Ca2+ influx upregulate calpain and induce apoptosis in PC12 cells.Brain Res,2000,852(2):326-334.
87. Reader S,Moutardier V,enizeau F.Tributyltin triggers apoptosis in trout hepatocytes :the role of Ca2+,protein kinase C and proteases.Biochim Biophys Acta, 1999,1448(3):473-485.
88. Miyake H,Hara I,Yamanaka K,et al. Calcium ionophore,ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels.J Urol, 1999,162(3 Pt1) :916-921.
89. Popescu BO,Cedazo-Minguez A,Popescu LM,et al. Caspase cleavage of exon 9 deleted presenilin-1 is an early event in apoptosis induced by calcium ionophore A 23187 in SH2SY5Y neuroblastoma cells. J Neurosci Res,2001,66 (1):122 - 134.
90. Zhang TC,Cao EH,Li JF,et al.Induction of apoptosis and inhibition of human gastric cancer MGC2803 cell growth by arsenic trioxide.Eur J Cancer, 1999, 35(8): 1258-1263.
91. Florio T,Thellung S,Arena S ,et al.Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.Eur J Endocrinol, 1999,141(4):396 - 408.
92. Orrenius S,Mcconkey DJ,Bellomo G,et al.Role of Ca2+ in toxic cell Killing.Trends Pharmacol Sci, 1989, 10(7) :281.
93. Miller WHJr,Schipper HM,Lee JS,et al.Mechanisms of action of arsenic trioxide.Cancer Res, 2002, 62(14):3893-3903.
1. Chen YJ, Shiao MS, Lee SS. Effect of Cordyceps sinensis on proliferation and diferentiation of human leukemic U937 cells. Life Sci, 1997, 60(25): 2439-2359.
2. Hsieh T, Chen SS, Wang X, et al. Regulation of androgen receptor and prostate specific antigen expression if the androgen-responsive human prostate LNCap cells by ethanolic extracts of Chinese herbal preparation PC-SPES. Biochem Mol Biol Int, 1997, 42(3): 535-544.
3. Spaulding-Albright N. A review of some herbal and relative products commonly used in cancer patients. J Am Diet Assoc, 1997(10Suppl 12), 97: S208-215.
4．刘福英，吕占军，主编．实验动物学[M]．北京：中国农业科技出版社，1997．21-24．
5．郭鹞，主编．人类疾病的动物模型[M]．北京：人民卫生出版社，1995．59-66．
6．卢耀增，主编．实验动物学[M]．北京：北京医科大学协和医科大学联合出版社，1995．228-235．
7．杨家和，钱其军，薛惠斌，等．局部注射小鼠白细胞介素-12逆转录病毒包装细胞对大鼠肝癌的治疗．中国肿瘤生物治疗杂志，1999，6：31-34．
8. Hirakawa N. Reconsinderation for the histogenesis and classification of DMBA-induced ovarian cancer. J Kurume Med Asso, 1993, 56: 283-291.
9．程湘，程天民，冉新泽，等．大鼠卵巢肿瘤模型的建立与初步观察．现代妇产科进展，2000，9：282-283．
10．高进，主编．癌的侵袭与转移[M]．北京：北京医科大学协和医科大学联合出版，1996．56-58．
11．高进．裸鼠建立的过程及其在肿瘤异体移植中的作用．国外医学肿瘤学分册，1981，(2)：52．
12．孙宪肪，汤钊猷．人癌转移模型研究进展．国外医学肿瘤学分册，1994，21(6)：321-324．
13. Agaus DB, Scher HI, Higgins SB, et al. Response of prostate cancer to anti-her-2/neu antibody in androgen-dependent and independent human Xenograft Models. Cancer Res, 1999, 59(19): 4761-4764.
14. Couillard US,Gutman M,Labrie F,et al.Effect of combined treatment with the pure antiestroen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenograft in nude mice.Cancer Res,1999,59(19):4857-4863.
15. Abramovitch R,Dafni H,Smouha E,et al.In vivo predication of vascular susceptibility to vascular endothdlial growth factor withdrawal: maginetic resonance imaging of C6 rat glioma in nude mice.Cancer Res, 1999, 59(19): 5012-5016.
16. Selig RA,White L,Gramacho C,et al.Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.Cancer Res,1998,58(3):473-478.
17. Morikawa K,Walker SM,Jessup J,et al.In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinoma implanted into nude mice.Cancer Res,1988,48:1943-1948.
18. Molthoff CF,Calame JJ,Pinedo HM,et al.Human ovarian cancer xenografts in nude mice : characterization and analysis of antigen expression. Int J Cancer, 1991, 47(1): 72-79.
19. Kelland LR.Ammine/amine platinum(IV)dicarboxylates : A lead to the discovery of a new generation of broad spectrum platinum-based anticancer drugs. Drugs of the Future,1993,18(6):555.
20. Mckeage MJ,Kelland LR,Boxall FE,et al.Schedule dependency of orally administeredbis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res, 1994, 54(15): 4118-4122.
21.Alagoz T,Buller RE,Anderson B,et al.Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer, 1995,75(9):2313-2322.
22. Hanna N,Davis TW,Fidler IJ.Envionmental and genetic factors determine the lever of NK activity of nude mice and aftrer their suitability as models for experimental metastasis. Int J Cancer, 1982,30:371-376.
23．施新猷,主编．医用实验动物学[M]．西安：陕西科学技术出版社,1989．128-150, 303
24．黄培根，沈淑静，莫梅英，等．六年中裸小鼠繁殖群动物自发性肿瘤发病情况研究．北京实验动物科学与管理，1994，11(1)：9-13．
25. Malik STA, East N, Boraschi D, et al. Effects of intraperitoneal recombinant inter leukin-1 B in intraperitoneal human ovariancancer xenograft model: comparison with the effects of tumor necrosis factor. Br J Cancer, 1992, 65(5): 661-666.
26. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clows memorial award lecture. Cancer Res, 1990, 50(19): 6130-6138.
27. Lee JJ, Liu D, Lee JS, et al. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst, 2001, 93(14): 1081-1088.
28. Shiba M, Kohno H, Kakizawa K, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer, 2000, 89(7): 1457-1465.
29. Barsky SH, Roth MD, Kleerup EC, et al. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst, 1998, 90(16): 1198-1205.
30．王允，周清华，陈桂枝，等．核增殖抗原表达基因Ki-67与人肺癌临床病理生理特征及其预后的关系．中国胸心血管外科临床杂志，2001，8(2)：103-105．
31. Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol-Int, 1999, 49(12): 1060-1066.
32. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol, 1995, 146(4): 876-887.
33. Kitaguchi S, Takeshima Y, Nishisaka T, et al. Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung. Hiroshima J Med Sci, 1998, 47(1): 17-25.
34. Santinelli A, Ranaldi R, Baccarini M, et al. Ploidy, proliferative activity, p53 and bcl-2 expression in bronchopulmonary carcinoids: relationship with prognosis. Pathol Res Pract, 1999, 195(7): 467-474.
35. Fujiwara M, Okayasu I, Takemura T, et al. Telomerase activity significantly correlates with chromosome alterations, cell differentiation, and proliferation in lung adenocarcinomas. Mod Pathot, 2000, 13(7): 723-729.
36. Hayashi Y, Fukayama M, Koike M, et al. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Acta Pathol Jpn, 1993, 43(6): 313-319.
37. Mizera NE, Dyszkiewicz W, Heider KH, et al. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour Biol, 2001, 22(1): 45-53.
38．王德江，孙雪飞，李希波．非小细胞肺癌iNOS表达及其与肿瘤细胞增殖关系的研究．山东大学学报医学版，2003，41(5)：517-520．
39. Demarchi LM, Reis MM, Palomino SA, et al. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol, 2000, 13(5): 511-520.
40. Shiba M, Kakizawa K, Kohno H, et al. Prognostic implication of Ki-67 thoracotomy in lung cancer patients. Ann Thorac Surg, 2001, 71 (6): 1765-1771.
41. Mehdi SA, Etzell JE, Newman NB, et al. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage Ⅰ and Ⅱ non-small cell lung cancer. Lung Cancer, 1998, 20(2): 99-108.
42. Komaki R, Milas L, Ro JY, et al. Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 1998, 40(4): 787-796.
43. Wang J, Wang Z, Chen M. Preliminary study on relationship among apoptosis and related gene, prognosis of lung cancer. Zhonghua Jie He He Hu Xi Za Zhi, 1997, 20(3): 141-144.
44. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res, 2000, 6(10): 4073-4081.
45. Lyons SK, Clarke AR. Apoptosis and carcinogenesis. Br Med Bull, 1997, 53 (3): 554-569.
46. Huang P, Oliff A. Signaling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol, 2001, 11 (8): 343-348.
47. Reed JC, Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death Differ, 2000, 7(12): 1145.
48. Arya J, Finlayson CA, Shames BD, et al. Stimulated apoptosis as an anti-neoplastic strategy. Surgery, 2000, 127(4): 366-369.
49. Debati K. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett, 2000, 112-113(4): 1-48.
50. White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia, 2001, 15 (7): 1011-1021.
51. Negoescu A. Apoptosis in cancer: therapeuticimplications. Histol Histopathol, 2000, 15(1): 281-297.
52. Mow BM, Blajeski AL, Chandra J, et al. Apoptosis and the response to anticancer therapy. Curr Opin Oncol, 2001, 13(6): 453-462.
53. Croce CM. How can we prevent cancer?. Proc Natl Acad Sci USA, 2001, 98(20): 10986-10988.
54. Negoescu A, Guillermet C, Lorimier P, et al. Importance of DNA fragmentation in apoptosis with regard to TUNEL specificity. Biomed Pharmacother, 1998, 52: 252-259.
55. Mirakian R, Nye K, Palazzo FF, et al. Methods for detecting apoptosis in thyroid disease. J Immunol Methods, 2002, 265(1-2): 161-175.
56. Kobayashi T, Ruan S, Jabbur JR, et al. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ, 1998, 5(7): 584-591.
57. Zhang H, Yousem SA, Franklin WA, et al. Differentiation and programmed cell death-related intermediate biomarkers for the development of non-small cell lung cancer: a pilot study. Hum Pathol, 1998, 29(9): 965-971.
58．温雪萍，程西安，王有恒，等．Bcl-2蛋白在肺癌组织中的表达及其意义．西安医科大学学报，2001，20(1)：41-42．
59．马红，马晓春，张玲，等．肺癌组织中p53和Bcl-2蛋白表达与血管新生的关系．中华内科杂志，2004，43(1)：59-60．
60. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med, 1993, 329: 690-694.
61．王巍，黄慧强，管忠震．Bcl-2和整合素α3蛋白在非小细胞肺癌中的表达及临床意义．中国癌症杂志，2004，14(3)：226-233．
62. Borner MM, Brousset P, Pfanner MB, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small cell lung cancer. Br J Cancer, 1999, 79(5-6): 952-958.
63．李潞，周清华，李虹，等．Bax基因产物表达与肺癌预后关系的研究．中国肺癌杂志，2000，3(3)：180-182。
64．何勇，李继良，李桃源．Bcl-2和Bax在非小细胞肺癌中的表达．中国肿瘤，2002，11(12)：738-740．
65．陆舜，张伟，时美萍，等．非小细胞肺癌凋亡相关基因Bcl-2和Bax表达及其与端粒酶的关系．临床内科杂志，2002，19(5)：369-370．
66．于文成，刘伟．PTEN、Bcl-2及Bax基因在非小细胞肺癌中的表达及意义．青岛大学医学院学报，2004，40(4)：97-100．
67. Li Y, Bhuiyan M, Mohammad RM, et al. Induction of apoptosis in breast cancer cells by TPA. Oncogene, 1998, 17: 2915-2920.
68. Brambilla E, Gazzeri S, Lantuejoul S, et al. p53 mutantimmunophenotype and deregulation of p53 t ransciption pat hway(Bcl-2, Bax, and waf-1) in precursor bronchial lesions of lung cancer. Clin cancer Res, 1998, 4 (7): 1609-1618.
69．杨炯，吴小军，丁续红，等．肺癌组织中Bcl-2和Bax的表达及其与细胞凋亡和增殖的关系．武汉大学学报(医学版)，2001，22(2)：120-122．
70．刘伟，于文成，秦筱梅．非小细胞肺癌Bcl-2及Bax蛋白的表达及其与细胞凋亡和增殖的关系．青岛大学医学院学报，2005，41(2)：149-151．
71．谢彤，祝家兴，左传田，等．细胞凋亡相关基因bcl-2与bax在肺癌组织中表达的意义．四川肿瘤防治，2001，14(3)：129-133．
72．秦建文，陈光瑾，王新允．非小细胞肺癌凋亡及相关基因Bcl-2和Bax的表达．天津医药，2005，33(5)：275-277．
73. Kagawa S, Gu J, Swisher SG, et al. Antitumor effect of adenovi rus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Research, 2000, 60(5): 1157-1161.
74. Jacques R, Petra D, Bernd W, et al. Antibody Response to the tumor-associated Inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 2000, 60(7): 1815-1817.
75. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early stage NSCLC. J Pathology, 2003, 200(5): 620-626.
76. Nakanishi K, Rawai T, Kumaki F, et al. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol, 2003, 120(5): 712-719.
77. Wang X, Chen S, Zhang Z. Expression of surviving gene and its relationship with expression of P53, c-myc, k-ras proteins in non-small-cell lung cancer. Zhonghua-Jie-He-He-Hu-Xi-Za-2Zhi, 2001, 24 (6): 371-374.
78．张晓宇，钟立厚，胡克，等．生存素在非小细胞肺癌中的表达及与细胞凋亡的关系．中国肺癌杂志，2004，7(2)：138-141．
79. Ikehara M, Oshita F, Kameda Y, et al. Expression of Survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep, 2002, 9(4): 835-838.
80．向敏峰，刘德森，陈发龙．非小细胞肺癌中Survivin蛋白与p63蛋白的表达及其相关性．广西医科大学学报，2005，22(2)：228-231．
81. Joseph B, Lewensohn R, Zhivotovsky B, et al. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci, 2000, 926(1): 204-216.
82. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer, 2001, 31 (1): 43-56.
83. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: Re-expession of survivin messager RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol, 1999, 17(7): 2100-2104.
84. Kren L, Brazdil J, Hermanova M, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol, 2004, 12(1): 44.
85. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting Survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res, 2000, 60 (11): 2805-2809.
86. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest, 2001, 108(7): 981-990.
87. Shen C, Buck A, PolatB, et al. Triplex-forming oligodeoxynucleotides targeting Survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer Gene Ther, 2003, 10(5): 403-410.
88．姚峰，陶琳，陈倩，等．凋亡抑制基因Survivin在非小细胞肺癌中的表达及其与Bcl-2、Bax蛋白表达的关系．中华实验外科杂志，2004，21(1)：84-87．
89. Lu CD, Altieri DC, Tanigawa N, et al. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res, 1998, 58: 1808-1812.
90. Tanaka K, Iwamoto S, Gon G, et al. Expression of surviving and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res, 2000, 6: 127-134.
91. Kasawaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survivial rates in colorectal cancer. Cancer Res, 1998, 58(22): 5071-5074.
92. Rohayerm J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumorassociated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 2000, 60(7): 1815-1817.
93. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, Caspase, and anti cancer drugs. Cancer Res, 1998, 58(23): 5315-5320.
94. Khanna N, Sen S, Sharma H, et al. S29 ribosomal protein induces apoptosis in H520 cells and sensitizes them to chemotherapy. Biochem Biophys Res Commun, 2003, 304 (1): 26-35.
2. Bast RC, Kule DW, Pollock RE, et al. Holland-Frei Cancer Medicine[M]. 5th Ed. Bc Decker, chap, 2000: 120.
3．李连弟，饶克勤，中国11市县肿瘤发病和死亡登记资料统计分析(1988年．1992年)．中国肿瘤，2000，9(10)：435-477．
4．林小萍，王庆生，刘新民．肺癌发病趋势及分析．天津医科大学学报，2000，6(2)：129-132．
5．蒋耀光，周清华，主编．现代肺癌外科学．北京：人民军医出版社，2003．460．
6．潘云华，潘琦，王泽时，等．复方三根制剂抗T739小鼠肺癌转移的实验研究．浙江中西医结合杂志，2005，15(2)：76-78．
7．冯正权，郭勇，朱宁希，等．复方三根制剂逆转多药耐药的实验研究．中国肿瘤，2003，12(6)：370-371．
8．林玲，章巧萍，俞丽霞，等．三根祛瘤方对DNA损伤的保护和对化疗药减毒增效作用的研究．浙江中医学院学报，1997，21(5)：30-32．
9．钟振国，张凤芬，甄汉深，等．美味猕猴桃根提取物抗肿瘤作用的实验研究．中医药学刊，2004，22(9)：1705-1707．
10．钟振国，张雯艳，张凤芬，等．中越猕猴桃根提取物的体外抗肿瘤活性研究。中药材，2005，28(3)：215-218．
11．张凤芬，钟振国，张雯艳，等．山梨猕猴桃根提取物的体外抗肿瘤活性研究．中医药学刊，2005，23(2)：261-263．
12．李昊，杨慧萍，杨凡等．藤梨根对胃癌细胞作用的实验研究河北中医，2004，26(4)：314-315．
13．金永日，桂明玉，马冰如，等．软枣猕猴桃根化学成分的研究．中国药学杂志．1998，33(7)：402-404．
14．季于彬．抗癌中药药理与应用．黑龙江：黑龙江科技出版社，1999．489．
15．陈德轩，潘立群．抗肿瘤植物药藤梨根．中药材，2004，27(2)：86-87．
16．翟延君，冯夏红，康廷国，等．软枣猕猴桃不同药用部位微量元素的含量测定．微量元素与健康研究，1996，13(3)：32-33．
17．朱秀山，许继平，黄德辉，等．壁虎藤梨根治疗胃癌临床及实验研究．中国民间疗 法，1999，(3)：43-44．
18．杭州肿瘤医院．草药藤梨根治疗癌症的情况调查．中草药通讯，1970，1(1)：18．
19．李蕾，金长娟．夏星方在食管癌粘液痰中的应用．现代中西医结合杂志，2000，9(15)：1445．
20．张新，孙华．余桂清治疗食管癌经验．中国中西医结合脾胃杂志，1999，7(3)：167．
21．闫洪飞，卢雯平．孙桂芝教授治疗消化道肿瘤的经验．中国中西医结合外科杂志，2002，8(1)：46．
22．杨继泉，张斌斌．中药治疗中晚期胃癌102例疗效分析．浙江中西医结合杂志，2000，10(6)：334-335．
23．郭勇，吴仙俐．大肠癌的中西医治疗规律初探．浙江中医学院学报，1992，16(4)：28．
24．周兴兆．唐福安论肺癌证治．浙江中医学院学报，2000，24(2)：45-46．
25．唐文秀．中医药治疗晚期原发性非小细胞肺癌临床观察．中医杂志，1994，35(5)：283．
26．夏黎明，林起铨，呈飞雪，等．中医药治疗原发性肺癌临床疗效探析．中国中医基础医学杂志，2001，7(8)：612-613．
27．周兰．中西医结合治疗中晚期恶性肿瘤50例．辽宁中医学院学报，2002，4(1)：45-46．
28．霍介格，杨炳奎．胶质瘤中医及中西医结合治疗进展．江苏中医药，2002，23(8)：44-46．
29．于志峰，戴锡孟．中医药治疗急性白血病的研究概况．天津中医，2000，17(4)：51-53．
30．阙克清．软枣猕猴桃抗癌作用的实验研究．湖南医学，1985，(5)：21．
31．林玲，章巧萍，俞丽霞，等．三根祛瘤方对小鼠S180的抗瘤和免疫作用的研究．中草药，1995，17(10)：33-35．
32．林玲，章巧萍，俞丽霞，等．三根祛瘤方对Lewis肺癌等的抗肿瘤作用实验研究．浙江中医学院学报，1995，19(1)：37-39．
33．张爱琴，王泽时．三根祛瘤方对大鼠胃癌癌前病变阻断机理实验研究．中国中西医结合杂志，1998，18(1)：35-36．
34．陈华．三根祛瘤方抗瘤作用研究．现代中西医结合杂志，2001，10(23)：2237-2239．
35．谢长生，周维顺，冯正权，等．复方三根制剂对MDR细胞株K562／ADR和K562／VCR逆转作用的研究．中国实验方剂学杂志，2003，9(4)：26-30．
36．郭勇，谢长生，冯正权．复方藤梨根制剂体外对MDR细胞株K562／ADR和K562／VCR细胞积聚和外排阿霉素(ADR)的影响研究．中国现代应用药学杂志，2002，19(4)：268-272．
37．张海波，姚庆华，郭勇，等．复方藤梨根制剂对PG细胞生长调控的研究．浙江中西医结合杂志，2004，14(10)：616-617．
38．姚庆华，郭勇，杨维泓，等，复方藤梨根制剂上调PG细胞细胞间隙连接通讯功能的研究，肿瘤研究与临床，2004，16(5)：302-304
39．尹丽慧，叶人，吴建波，等．蔡氏扶正消症汤对胃癌细胞增殖的抑制作用研究．中医药学刊，2005，23(3)：473-475．
40．张光霁．藤蟾方抑瘤及其诱导肿瘤细胞凋亡的实验研究。浙江临床医学，2004，6(5)：356-357．
41．张光霁，申力．藤蟾方对荷瘤小鼠免疫功能影响的实验研究辽宁中医杂志，2004，31(6)：523．
42．张光霁．藤蟾方对S_(180)小鼠p53和PCNA蛋白表达的影响．现代中西医结合杂志，2004，13(12)：1566-1567．
43．王文萍，姜良铎，饭乡正明，等．肠积消对IFN_γ的诱导及肺转移的抑制．中国中医基础医学杂志，2001，7(12)：903-904．
44．王文萍，姜良铎，王垂杰，等．中药复方肠安泰胶囊对大肠癌肺转移模型小鼠肠粘膜T细胞及NK细胞的诱导．北京中医药大学学报，2001，24(4)：34-36．
45. Mosmain T, Murphy PC, Henderson FW. Rapid colorunetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Imm Method, 1983, 65(2): 55-59.
46. Carmichael J, Degraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res, 1987, 47: 936-942.
47．张卓然，主编。培养细胞学与细胞培养技术．上海：上海科学技术出版社，2004。310．
48. Salmon SE. Humen tumor colony assay and chemosensitivity testing. Cancer Treat Rep, 1984, 68(1): 117-125.
49．韩锐，主编．抗癌药物研究与实验技术．北京：北京医科大学中国协和医科大学联合出版社，1997．4．
50. JI Whang, HI Moon, OP Zee. Phytochemical Constituents of Actinidia arguta. Korean Journal of Pharmacognosy, 2000, 31(3): 357-363.
51．高慧，傅松滨，董辉．肿瘤中p16基因的研究进展国外医学遗传学分册，1999，22(2)：61-65．
52. Schafer KA .The cell cycle:a review.Vet Pathol, 1998,35(6):461-478.
53. Barlogie B,Raber MN,Schumann J,et al. Flow cytometry inclinical cancer research. Cacer Res, 1983, 43(9):3982.
54. Visakorpi T,Holli K,Hakama M.High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma.Acta Oncol, 1995,34(5):605.
55. Stein H,Gerdes J,Kirchner H,et al.Immunohistological analysis of Hodgkin'sand Sternberg-reed cells:detection of a new antigen and evidence for selective IgG uptake in the absence of B cell,T cell and histiocytic markers.J Cancer Res Clin Oncol,1981,101(1):125-134.
56. Gerdes J, Schwab U,Lemke H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.Int J Cancer, 1983,31(1): 13-20.
57. Schluter C,Duchrow M,Wohlenberg C,et al.The cell proliferation-associated nuclear antigen of antibody Ki-67:A very large,ubiquitous nuclear protein with numerous repeated element,representing a new kind of cell cycle maintaining protein. J Cell Biol, 1993,123:513-522.
58. Schluter C,Duchrow M,Wohlenberg C,et al.Molecular cloning of the cell proliferation-associated nuclear antigen defined dy antibody Ki-67:a unique gene encoding for a new PEST protein.J Cell Biol, 1993, 123(4): 635-642.
59. Bruno S,Darzynkiewicz Z.Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells.Cell Prolif, 1992,25(1): 31-40.
60. Gerds J,Li L,Schluter C,et al.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined dy monoclonal antibody Ki-67.Am J Pathol, 1991, 138(4):867-873.
61.Verheijen R,Kuijpers HJ,Schlingemann RO,et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen.I.Intracellular localization during interphase. J Cell Sci,1989,92(pt1): 123-130.
62. Verheijen R,Kuijpers HJ,Van Driel R,et al.Ki-67 detects a nuclear matrix- associated proliferation-related antigen.II.Localization in mitotic cells and association with chromosomes. J Cell Sci, 1989, 92: 531-540.
63. Sawhney N, Hall PA. Ki-67 structure, function, and new antibodies. J Pathol, 1992. 168(2): 161-162.
64. Sasaki K, Murakami T, Kawasaki M, et al. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Pathol, 1987, 133(3): 579-584.
65. Duchrow M, Schulter C, Wohlenberg C, et al. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined dy monoclonal antibody Ki-67. Cell Prolif, 1996, 29(1): 1-12.
66. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhance ment method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histoche Cytoche, 1991, 39(6): 741-748.
67. Key G, Meggetto F, Becker MH, et al. Immunobiochemical characterization of the antigen detected by monoclonal antibody IND. 64. Evidence that IND. 64 reacts with the cell proliferation associated nuclear antigen previously defined by Ki-67. Virchows Arch B Cell Pathol Incl Mol Pathol, 1992, 62(4): 259-262.
68. Key G, Petersen JL, Becher MH, et al. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J Clin Pathol, 1993, 46(12): 1080-1084.
69. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 1984, 133(4): 1710-1715.
70. Linden MD, Torres FX, Kubus J, et al. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol, 1992, 97(SSuppl 1): S4-13.
71. Pich A, Ponti R, Valente G, et al. MIB, Ki-67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol, 1994, 47(1): 18-22.
72．许玲，刘嘉湘．益肺抗瘤饮抑制肺癌细胞增殖的实验研究．中国中西医结合杂志，1996．16(8)：486-488．
73．程小丽，陈葳，周冬枝，等．益气养血保元对肺癌细胞Ki-67的影响。现代中医，1999，12(4)：39-40．
1. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer, 1994, 73(8): 2013-2026
2．李学军，杨叔禹．中医药促进细胞凋亡机理研究进展．中国中医基础医学杂志，2003，9(1)：73-74．
3．李晓波，季莉莉，王钊．中药对细胞凋亡影响的研究进展．中药材，2002，25(2)：135-139．
4．钟振国，张凤芬，甄汉深，等．美味猕猴桃根提取物抗肿瘤作用的实验研究．中医药学刊，2004，22(9)：1705-1707．
5．李昊，杨慧萍，杨凡等．藤梨根对胃癌细胞作用的实验研究．河北中医，2004，26(4)：314-315．
6．张光霁．藤蟾方抑瘤及其诱导肿瘤细胞凋亡的实验研究．浙江临床医学，2004，6(5)：356-357．
7．沈洁云，燕忠生．中药抗肿瘤作用机理研究进展．中医杂志，2000，41(7)：437．
8．涂硕，韦星．中药诱导肺癌细胞凋亡的研究进展．江西医学院学报，2005，4(3)：164-166．
9. Bour ES, Ward LK, Cornman GA, et al. Tumor necrosis factor-alpha-induced apoptosis in hepatocytes in long-term culture.Am J Pathol, 1996, 148: 485-495.
10. Hengarter, M. Death by crowd control. Science, 1998, 281 (5381): 1298-1299.
11. Cummings MC, Winterford CM, Walker NI. Apoptosis. Am J Surg Pathol, 1997, 21: 88-101.
12. Granville DJ, Carthy CM, Hunt DWC, et al. Apoptosis: molecule aspects of cell death and disease. Lab Invest, 1998, 78: 893-913.
13. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer, 1972, 26: 239-257.
14. Kuan NK, Passaro E. Apoptosis: Programmed cell death. Arch Surg, 1998, 133: 773-775.
15. Hacker G. The morphology of apoptosis. Cell Tissue Res, 2000, 301 (1): 5-17.
16. Nagata S, Golstein P. The Fas death factor. Science, 1995, 267: 1449-1456.
17. Wyllie A. An endonuclease at last. Nature, 1998, 391: 20-21.
18. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytest riggers specific recognition and removal by macrophages. J Immunol, 1992, 148: 2207-2216.
19. Wyllie AH. Apoptosis: an overview. Br Med Bull, 1997, 53: 451-465.
20. Peter ME,Heufelder AE,Hengartner MD.Advances in apoptosis research .Proc Natl Acad Sci,1997,94:12736-12737.
21. Hetts SW.To die or not to die:an overview of apoptosis and its role in disease. JAMA, 1998,279(4):300-307.
22. Green,DR .Apoptotic pathways: paper wraps stone blunts scissors. Cell,2000,102 (1) .1-4.
23. Lyons SK,Clarke AR.Apoptosis and carcinogenesis.Br Med Bull,1997,53 (3): 554-569.
24. Huang P,Oliff,A. Signaling pathways in apoptosis as potential targets for cancer therapy.Trends Cell Biol,2001,11 (8):343-348.
25. Makin G,Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?.Breast Cancer Res,2001,3(3):150-153.
26. Haq R,Zanke B.In hibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance.Cancer Metastasis Rev, 1998,17(2): 233-239.
27. Inoue S,Salah-Eldin AE,Omoteyama K. Apoptosis and anticancer drug resistance. Hum Cell, 2001, 14(3):211-221.
28. Ravi D, Panikkar KR,Nair MK,et al.Apoptosis:future directions in cancer therapy .Natl Med J India, 2000,13(2):71-78.
29. Kolenko VM,Uzzo RG,Bukowski R,et al.Caspase-dependent and -independent death pathways in cancer therapy.Apoptosis,2000,5(1): 17-20.
30. Kaufmann SH,Earnshaw WC.Induction of apoptosis by cancer chemotherapy.Exp Cell Res,2000,256(1):42-49.
31. Makin G.Targeting apoptosis in cancer chemotherapy.Expert Opin Ther Targets, 2002, 6(1):73-84.
32. Johnstone RW,Ruefli AA,Lowe SW.Apoptosis:a link between cancer genetics and chemotherapy.Cell,2002,108(2):153-164.
33. Gong JP,Traganos F,Darzynkiewicz Z.A selective procedure for DNA extraction from apoptotic cells appliabie for gel electrophoresis and flow cytometry.Analy Biochem,1994,218:314-319.
34. Liming P,Bradely CJ,Liu JJ. The correlativity analysis of six methods of detecting apoptosis.Chin Med Sci J,1999,14(3):145-151.
35.Nicoletti I,Migliorati G,Pagliaui MC,et al. Arapid and simple method for measuring thymocyte apoptosiss by propidium iodide staining and flow cytometry.J Immunol Methods, 1991, 139(2):271-279.
36. Huschtscha LI,Jeitner TM, Anderson CE, et al. Identification of apoptotic and necrotc human leukemiac cells by flow cytometry.Experimental Cell Res, 1994,212:161-165.
37. Mirakian R,Nye K,Palazzo FF,et al.Methods for detecting apoptosis in thyroid disease.J Immunol Methods,2002,265 (1-2): 161-175.
38. Stassi G,Todaro M,Bucchieri F,et al. Fas/Fas ligand-driven T cell apoptosis as a consequence of infective thyroid immunop rivilege.J mmunol, 1999,162: 263-267.
39. Bretz JD,Baker JR.Apoptosis and autoimmune thyroid disease: following a TRAIL to thyroid destruction?. Clin Endocrinol,2001,55:1-11.
40. Kischkel FC,Lawrence DA,Chuntharapai A,et al.Apo2L/TRA IL-dependent recruitment of endogenous FADD and Caspase-8 to death receptors 4 and 5.Immunity, 2000,12 (6): 611-620.
41. Rodriguez M,Schaper J. Apoptosis : measurement and technical issues. J Mol Cell Cardio,2005,38(1): 15-20.
42. Kobayashi T,Ruan S,Jabbur JR,et al.Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ,1998,5(7):584-591.
43. Borner C.The Bcl-2 protein family:sensors and checkpoints for life- or-death decisions.Mol Immunol,2003,39:615-647.
44. Vander Heiden MG,Chandel NS,Williamson EK,et al.Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria.Cell, 1997,91(5): 627-637.
45. Kroemer G, Zamzami N, Susin SA. Mitochondrial, control of apoptosis. Immunol Today, 1997,18(1):44-51.
46. Scorrano L,korsmeyer SJ.Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun,2003,304:437-444.
47. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins.J Cell Med, 2003,7:249-257.
48. Sprick MR,Walczak H.The interplay between the bcl-2 family and death receptor-mediated apoptosis.Biochim Biophys Acta, 2004,1644:125-132.
49. Cory S,Adams JM.The Bcl-2 family regulators of the cellular life-or-death switch. Nat Rev Cancer, 2002,2:647-656.
50. Farrow SN,White JH,Martinou I,et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature,1995,374(6524):731-733.
51. Fernandez MC,Bick RJ.Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+.Oncogene, 1996,12(11): 2259-2266.
52. Haddad JJ.On the antioxidant mechanisms of Bcl-2: a retrospective of NF-kappaB signaling and oxidative stress. Biochem Biophys Res commim, 2004,322:355-363.
53. Chen GG,Liang NC,Lee JF,et al.Over-expression of Bcl-2 against Pteris semipinnata L-induced apoptosis of human colon cancer cells via a NF-kappa B-related pathway. Apoptosis, 2004,9:619-627.
54. Jiang M,Milner J.Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells.Genes Dev,2003,17(7):832-837.
55. Godefroy N,Bouleau S,Gruel G,et al. Transcriptional repression by p53 promotes a Bcl-2-insensitive and mitochondria-independent pathway of apoptosis. Nucleic Acids Res,2004,32:4480-4490.
56. Oltvai ZN,Milliman CL,Korsmeyer SL.Bcl-2 heterodimerizes in vivo with a conserved homdog ,Bax,that accelerates programmed cell death.cell, 1993, 74(4): 609-619.
57. Apte SS,Mattei MG,Olsen BR.Mapping of the human Bax gene to chromosome 19q13.3-19q13.4 and isolation of a novel alternatively spliced transcript,Bax delat.Genomics,1995,26:592-594.
58. Coultas L,Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol, 2003,13:115-123.
59. Krajewski S,Krajewska M,Shabaik A,et al.Immunohistochemical determination of in vivo diatribution of Bax,a dominant inbitor of Bcl-2.Am J Pathol, 1994,145: 1323-1336.
60. Wolter KG, Hsu YT, Smith CL, et al. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol,1997,139(5): 1281-1292.
61. Antonsson B,Conti F,Ciavatta A,et al. Inhibition, of Bax channel-forming activity by Bcl-2. Science,1997 ,277(5324) :370-372.
62. Li Y,Bhuiyan M,Mohammad RM,et al. Induction of apoptosis in breast cancer cells by TPA.Oncogene, 1998,17:2915-2920.
63. Zami N,Brenner C,Marzo I Susin SA,et al. Subcelluar and submitochondrial mode of action of Bcl-2-like oncoproteins.Oncogene, 1998,16:2265-2282.
64. Korsmeyer SJ .BCL-2 gene family and the regulation of programmed cell death. Cancer Research, 1999, 59(Suppl):1693-1700.
65. Adams JM,Cory S.The Bcl-2 protein family: Arbittrs of Cell Survival.Science, 1998,281:1322-1326.
66. Deveraux GL,Reed JC. IAP family proteinssuppressor of apoptosis. Genes Dev, 1999, 13:239-252.
67. Lacasse EC,Baird S,Kormeluk R,et al. The inhibitors of apoptosis (IAPs)and their emerging role in cancer.Oncogene, 1998,17:3247-3259.
68. Ambrosini G,Adida C,Altier Dc,et al. A novel anti-apoptosis gene, surviving expressed in cancer and lymphoma .Nat Med, 1997, 3(8):917-912.
69. Ambrosini G,Adida C,Sirugo G,et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998,273 (18) : 11177-11182.
70. Chantalat L,Skoufias DA,kleman JP,et al. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual α-helicals extensions.Mol Cell,2000,6 (1): 183-189.
71.Akoufias DA,Mollinari C,Lacrax FB,et al.Human survivin is a kinetochore- associated passenger protein. J Cell Biol,2000,151(7): 1575-1582.
72. Gianani R,Jarboe E,Orlicky D,et al. Expression of Survivin in normal, hyperplastic and neoplastic colonic mucosa.Hum Pathol,2001,32(1):119 - 125.
73. Shinozawa I,Inokuchi K,Wakahayashi I,et al.Disturbed expression of the anti -apoptosis gene,Survivin and EPR-1 in hematological malignancies.Leuk Res, 2000,24(11): 965-970.
74. Shin S,Sung BJ,Cho Ys,et al.An anti-apoptotic protein human survivin is a direct inhibitor of Caspase-3 and Caspase-7.Biochemistry.2001, 40(4):1117-1123.
75. Adida C,Crotty PL,McGrath J,et al.Developmentaly regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse diferentiation. Am J Pathol, 1998,152(1):43-49.
76. Andrade F,Roy S,Nicholson D,et al.Granzyme B directly and efficiently cleaves several downstream Caspase substrates:implications for CTL-induced apoptosis.Immunity, 1998, 8(4):451-460.
77. Ito T,Shirak K,Sugimoto K,et al. Survivin promotes cell proliferation in human hepatocelluarcarcinoma.Hepatology,2000,31(5):1080-1085.
78. Suzuki A,Ito T,Kawano H,et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas - mediated cell death. Oncogene,2000,19(10): 1346-1353.
79. Altieri Dc. Coupling apoptosis resistance to the cellular stress response : The IAP-Hsp90 connection in cancer. Cell Cycle,2004,3 (3) 255-256.
80. Du C,Fang M,Li Y,et al.Smac,a mitochondrial protein that promotes cytochrome c-dependent Caspase activation by eliminating LAP inhibition. Cell, 2000,102:33-42.
81. Verhagen AM,Ekert PG,Pakusch M,et al.Identification of DIABLO,a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 2000,102(1):43-53.
82. Li F,Ambrosini G,Chu EY,et al.Control of apoptosis and mitotic spindle checkpoint by surviving.Nature, 1998,396(6711):580-584.
83. Lin FR,Wang Y,Wang RQ,et al. Expression of survivin,Fas,bcl-2 and bax in bone marrow cells from acute myeloid leukemia patients and its clinical significance. Zhongguo-Shi-Yan-Xue-Ye-Xue-Za-Zhi,2003,11(3): 259-262.
84. Nguyen VN,Mirejovsky P,Mirejovsky T,et al.Expression of cyclin Dl,Ki-67 and PCNA in non - small cell lung cancer: prognostic significance and comparion with P53 and Bcl-2. Acta Histochem,2000,102(3): 328-338.
85. Tamm I,Wang Y,Sausville E,et al.IAP-family protein survivin inhibits Caspase activity and apoptosis induced by Fas(CD95),Bax,Caspase,and anti cancer drags. Cancer Res, 1998,58(23):5315-5320.
86. Ray SK,Fidan M,Nowak M.Oxidative stress and Ca2+ influx upregulate calpain and induce apoptosis in PC12 cells.Brain Res,2000,852(2):326-334.
87. Reader S,Moutardier V,enizeau F.Tributyltin triggers apoptosis in trout hepatocytes :the role of Ca2+,protein kinase C and proteases.Biochim Biophys Acta, 1999,1448(3):473-485.
88. Miyake H,Hara I,Yamanaka K,et al. Calcium ionophore,ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels.J Urol, 1999,162(3 Pt1) :916-921.
89. Popescu BO,Cedazo-Minguez A,Popescu LM,et al. Caspase cleavage of exon 9 deleted presenilin-1 is an early event in apoptosis induced by calcium ionophore A 23187 in SH2SY5Y neuroblastoma cells. J Neurosci Res,2001,66 (1):122 - 134.
90. Zhang TC,Cao EH,Li JF,et al.Induction of apoptosis and inhibition of human gastric cancer MGC2803 cell growth by arsenic trioxide.Eur J Cancer, 1999, 35(8): 1258-1263.
91. Florio T,Thellung S,Arena S ,et al.Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.Eur J Endocrinol, 1999,141(4):396 - 408.
92. Orrenius S,Mcconkey DJ,Bellomo G,et al.Role of Ca2+ in toxic cell Killing.Trends Pharmacol Sci, 1989, 10(7) :281.
93. Miller WHJr,Schipper HM,Lee JS,et al.Mechanisms of action of arsenic trioxide.Cancer Res, 2002, 62(14):3893-3903.
1. Chen YJ, Shiao MS, Lee SS. Effect of Cordyceps sinensis on proliferation and diferentiation of human leukemic U937 cells. Life Sci, 1997, 60(25): 2439-2359.
2. Hsieh T, Chen SS, Wang X, et al. Regulation of androgen receptor and prostate specific antigen expression if the androgen-responsive human prostate LNCap cells by ethanolic extracts of Chinese herbal preparation PC-SPES. Biochem Mol Biol Int, 1997, 42(3): 535-544.
3. Spaulding-Albright N. A review of some herbal and relative products commonly used in cancer patients. J Am Diet Assoc, 1997(10Suppl 12), 97: S208-215.
4．刘福英，吕占军，主编．实验动物学[M]．北京：中国农业科技出版社，1997．21-24．
5．郭鹞，主编．人类疾病的动物模型[M]．北京：人民卫生出版社，1995．59-66．
6．卢耀增，主编．实验动物学[M]．北京：北京医科大学协和医科大学联合出版社，1995．228-235．
7．杨家和，钱其军，薛惠斌，等．局部注射小鼠白细胞介素-12逆转录病毒包装细胞对大鼠肝癌的治疗．中国肿瘤生物治疗杂志，1999，6：31-34．
8. Hirakawa N. Reconsinderation for the histogenesis and classification of DMBA-induced ovarian cancer. J Kurume Med Asso, 1993, 56: 283-291.
9．程湘，程天民，冉新泽，等．大鼠卵巢肿瘤模型的建立与初步观察．现代妇产科进展，2000，9：282-283．
10．高进，主编．癌的侵袭与转移[M]．北京：北京医科大学协和医科大学联合出版，1996．56-58．
11．高进．裸鼠建立的过程及其在肿瘤异体移植中的作用．国外医学肿瘤学分册，1981，(2)：52．
12．孙宪肪，汤钊猷．人癌转移模型研究进展．国外医学肿瘤学分册，1994，21(6)：321-324．
13. Agaus DB, Scher HI, Higgins SB, et al. Response of prostate cancer to anti-her-2/neu antibody in androgen-dependent and independent human Xenograft Models. Cancer Res, 1999, 59(19): 4761-4764.
14. Couillard US,Gutman M,Labrie F,et al.Effect of combined treatment with the pure antiestroen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenograft in nude mice.Cancer Res,1999,59(19):4857-4863.
15. Abramovitch R,Dafni H,Smouha E,et al.In vivo predication of vascular susceptibility to vascular endothdlial growth factor withdrawal: maginetic resonance imaging of C6 rat glioma in nude mice.Cancer Res, 1999, 59(19): 5012-5016.
16. Selig RA,White L,Gramacho C,et al.Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.Cancer Res,1998,58(3):473-478.
17. Morikawa K,Walker SM,Jessup J,et al.In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinoma implanted into nude mice.Cancer Res,1988,48:1943-1948.
18. Molthoff CF,Calame JJ,Pinedo HM,et al.Human ovarian cancer xenografts in nude mice : characterization and analysis of antigen expression. Int J Cancer, 1991, 47(1): 72-79.
19. Kelland LR.Ammine/amine platinum(IV)dicarboxylates : A lead to the discovery of a new generation of broad spectrum platinum-based anticancer drugs. Drugs of the Future,1993,18(6):555.
20. Mckeage MJ,Kelland LR,Boxall FE,et al.Schedule dependency of orally administeredbis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res, 1994, 54(15): 4118-4122.
21.Alagoz T,Buller RE,Anderson B,et al.Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer, 1995,75(9):2313-2322.
22. Hanna N,Davis TW,Fidler IJ.Envionmental and genetic factors determine the lever of NK activity of nude mice and aftrer their suitability as models for experimental metastasis. Int J Cancer, 1982,30:371-376.
23．施新猷,主编．医用实验动物学[M]．西安：陕西科学技术出版社,1989．128-150, 303
24．黄培根，沈淑静，莫梅英，等．六年中裸小鼠繁殖群动物自发性肿瘤发病情况研究．北京实验动物科学与管理，1994，11(1)：9-13．
25. Malik STA, East N, Boraschi D, et al. Effects of intraperitoneal recombinant inter leukin-1 B in intraperitoneal human ovariancancer xenograft model: comparison with the effects of tumor necrosis factor. Br J Cancer, 1992, 65(5): 661-666.
26. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clows memorial award lecture. Cancer Res, 1990, 50(19): 6130-6138.
27. Lee JJ, Liu D, Lee JS, et al. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst, 2001, 93(14): 1081-1088.
28. Shiba M, Kohno H, Kakizawa K, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer, 2000, 89(7): 1457-1465.
29. Barsky SH, Roth MD, Kleerup EC, et al. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst, 1998, 90(16): 1198-1205.
30．王允，周清华，陈桂枝，等．核增殖抗原表达基因Ki-67与人肺癌临床病理生理特征及其预后的关系．中国胸心血管外科临床杂志，2001，8(2)：103-105．
31. Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol-Int, 1999, 49(12): 1060-1066.
32. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol, 1995, 146(4): 876-887.
33. Kitaguchi S, Takeshima Y, Nishisaka T, et al. Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung. Hiroshima J Med Sci, 1998, 47(1): 17-25.
34. Santinelli A, Ranaldi R, Baccarini M, et al. Ploidy, proliferative activity, p53 and bcl-2 expression in bronchopulmonary carcinoids: relationship with prognosis. Pathol Res Pract, 1999, 195(7): 467-474.
35. Fujiwara M, Okayasu I, Takemura T, et al. Telomerase activity significantly correlates with chromosome alterations, cell differentiation, and proliferation in lung adenocarcinomas. Mod Pathot, 2000, 13(7): 723-729.
36. Hayashi Y, Fukayama M, Koike M, et al. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Acta Pathol Jpn, 1993, 43(6): 313-319.
37. Mizera NE, Dyszkiewicz W, Heider KH, et al. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour Biol, 2001, 22(1): 45-53.
38．王德江，孙雪飞，李希波．非小细胞肺癌iNOS表达及其与肿瘤细胞增殖关系的研究．山东大学学报医学版，2003，41(5)：517-520．
39. Demarchi LM, Reis MM, Palomino SA, et al. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol, 2000, 13(5): 511-520.
40. Shiba M, Kakizawa K, Kohno H, et al. Prognostic implication of Ki-67 thoracotomy in lung cancer patients. Ann Thorac Surg, 2001, 71 (6): 1765-1771.
41. Mehdi SA, Etzell JE, Newman NB, et al. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage Ⅰ and Ⅱ non-small cell lung cancer. Lung Cancer, 1998, 20(2): 99-108.
42. Komaki R, Milas L, Ro JY, et al. Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 1998, 40(4): 787-796.
43. Wang J, Wang Z, Chen M. Preliminary study on relationship among apoptosis and related gene, prognosis of lung cancer. Zhonghua Jie He He Hu Xi Za Zhi, 1997, 20(3): 141-144.
44. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res, 2000, 6(10): 4073-4081.
45. Lyons SK, Clarke AR. Apoptosis and carcinogenesis. Br Med Bull, 1997, 53 (3): 554-569.
46. Huang P, Oliff A. Signaling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol, 2001, 11 (8): 343-348.
47. Reed JC, Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death Differ, 2000, 7(12): 1145.
48. Arya J, Finlayson CA, Shames BD, et al. Stimulated apoptosis as an anti-neoplastic strategy. Surgery, 2000, 127(4): 366-369.
49. Debati K. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett, 2000, 112-113(4): 1-48.
50. White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia, 2001, 15 (7): 1011-1021.
51. Negoescu A. Apoptosis in cancer: therapeuticimplications. Histol Histopathol, 2000, 15(1): 281-297.
52. Mow BM, Blajeski AL, Chandra J, et al. Apoptosis and the response to anticancer therapy. Curr Opin Oncol, 2001, 13(6): 453-462.
53. Croce CM. How can we prevent cancer?. Proc Natl Acad Sci USA, 2001, 98(20): 10986-10988.
54. Negoescu A, Guillermet C, Lorimier P, et al. Importance of DNA fragmentation in apoptosis with regard to TUNEL specificity. Biomed Pharmacother, 1998, 52: 252-259.
55. Mirakian R, Nye K, Palazzo FF, et al. Methods for detecting apoptosis in thyroid disease. J Immunol Methods, 2002, 265(1-2): 161-175.
56. Kobayashi T, Ruan S, Jabbur JR, et al. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ, 1998, 5(7): 584-591.
57. Zhang H, Yousem SA, Franklin WA, et al. Differentiation and programmed cell death-related intermediate biomarkers for the development of non-small cell lung cancer: a pilot study. Hum Pathol, 1998, 29(9): 965-971.
58．温雪萍，程西安，王有恒，等．Bcl-2蛋白在肺癌组织中的表达及其意义．西安医科大学学报，2001，20(1)：41-42．
59．马红，马晓春，张玲，等．肺癌组织中p53和Bcl-2蛋白表达与血管新生的关系．中华内科杂志，2004，43(1)：59-60．
60. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med, 1993, 329: 690-694.
61．王巍，黄慧强，管忠震．Bcl-2和整合素α3蛋白在非小细胞肺癌中的表达及临床意义．中国癌症杂志，2004，14(3)：226-233．
62. Borner MM, Brousset P, Pfanner MB, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small cell lung cancer. Br J Cancer, 1999, 79(5-6): 952-958.
63．李潞，周清华，李虹，等．Bax基因产物表达与肺癌预后关系的研究．中国肺癌杂志，2000，3(3)：180-182。
64．何勇，李继良，李桃源．Bcl-2和Bax在非小细胞肺癌中的表达．中国肿瘤，2002，11(12)：738-740．
65．陆舜，张伟，时美萍，等．非小细胞肺癌凋亡相关基因Bcl-2和Bax表达及其与端粒酶的关系．临床内科杂志，2002，19(5)：369-370．
66．于文成，刘伟．PTEN、Bcl-2及Bax基因在非小细胞肺癌中的表达及意义．青岛大学医学院学报，2004，40(4)：97-100．
67. Li Y, Bhuiyan M, Mohammad RM, et al. Induction of apoptosis in breast cancer cells by TPA. Oncogene, 1998, 17: 2915-2920.
68. Brambilla E, Gazzeri S, Lantuejoul S, et al. p53 mutantimmunophenotype and deregulation of p53 t ransciption pat hway(Bcl-2, Bax, and waf-1) in precursor bronchial lesions of lung cancer. Clin cancer Res, 1998, 4 (7): 1609-1618.
69．杨炯，吴小军，丁续红，等．肺癌组织中Bcl-2和Bax的表达及其与细胞凋亡和增殖的关系．武汉大学学报(医学版)，2001，22(2)：120-122．
70．刘伟，于文成，秦筱梅．非小细胞肺癌Bcl-2及Bax蛋白的表达及其与细胞凋亡和增殖的关系．青岛大学医学院学报，2005，41(2)：149-151．
71．谢彤，祝家兴，左传田，等．细胞凋亡相关基因bcl-2与bax在肺癌组织中表达的意义．四川肿瘤防治，2001，14(3)：129-133．
72．秦建文，陈光瑾，王新允．非小细胞肺癌凋亡及相关基因Bcl-2和Bax的表达．天津医药，2005，33(5)：275-277．
73. Kagawa S, Gu J, Swisher SG, et al. Antitumor effect of adenovi rus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Research, 2000, 60(5): 1157-1161.
74. Jacques R, Petra D, Bernd W, et al. Antibody Response to the tumor-associated Inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 2000, 60(7): 1815-1817.
75. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early stage NSCLC. J Pathology, 2003, 200(5): 620-626.
76. Nakanishi K, Rawai T, Kumaki F, et al. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol, 2003, 120(5): 712-719.
77. Wang X, Chen S, Zhang Z. Expression of surviving gene and its relationship with expression of P53, c-myc, k-ras proteins in non-small-cell lung cancer. Zhonghua-Jie-He-He-Hu-Xi-Za-2Zhi, 2001, 24 (6): 371-374.
78．张晓宇，钟立厚，胡克，等．生存素在非小细胞肺癌中的表达及与细胞凋亡的关系．中国肺癌杂志，2004，7(2)：138-141．
79. Ikehara M, Oshita F, Kameda Y, et al. Expression of Survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep, 2002, 9(4): 835-838.
80．向敏峰，刘德森，陈发龙．非小细胞肺癌中Survivin蛋白与p63蛋白的表达及其相关性．广西医科大学学报，2005，22(2)：228-231．
81. Joseph B, Lewensohn R, Zhivotovsky B, et al. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci, 2000, 926(1): 204-216.
82. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer, 2001, 31 (1): 43-56.
83. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: Re-expession of survivin messager RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol, 1999, 17(7): 2100-2104.
84. Kren L, Brazdil J, Hermanova M, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol, 2004, 12(1): 44.
85. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting Survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res, 2000, 60 (11): 2805-2809.
86. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest, 2001, 108(7): 981-990.
87. Shen C, Buck A, PolatB, et al. Triplex-forming oligodeoxynucleotides targeting Survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer Gene Ther, 2003, 10(5): 403-410.
88．姚峰，陶琳，陈倩，等．凋亡抑制基因Survivin在非小细胞肺癌中的表达及其与Bcl-2、Bax蛋白表达的关系．中华实验外科杂志，2004，21(1)：84-87．
89. Lu CD, Altieri DC, Tanigawa N, et al. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res, 1998, 58: 1808-1812.
90. Tanaka K, Iwamoto S, Gon G, et al. Expression of surviving and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res, 2000, 6: 127-134.
91. Kasawaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survivial rates in colorectal cancer. Cancer Res, 1998, 58(22): 5071-5074.
92. Rohayerm J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumorassociated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 2000, 60(7): 1815-1817.
93. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, Caspase, and anti cancer drugs. Cancer Res, 1998, 58(23): 5315-5320.
94. Khanna N, Sen S, Sharma H, et al. S29 ribosomal protein induces apoptosis in H520 cells and sensitizes them to chemotherapy. Biochem Biophys Res Commun, 2003, 304 (1): 26-35.